Fundraising Fox
FlightPath
Birmingham, US · Founded 2019 · 3 employees on LinkedIn · 5 known investors
Find your way into FlightPath
Each arrow is one introduction. Sign up to fill in the first one.
Ask Tahir D'Mello to introduce you to Matt Tindall
You →Tahir · together at FlightPath →Matt
Sign up to find every way you can get introduced to FlightPath
- Your email: who you already know at FlightPath, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the FlightPath team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Flightpath Biosciences develops microbiome-sparing, pathogen-specific drug candidates to treat infection-associated diseases by selectively targeting harmful bacteria while preserving healthy microbial communities. The company focuses on small molecule therapeutics for chronic and complex diseases, particularly those linked to pathogenic bacteria such as Crohn's disease.
Founders & leadership
FlightPath was founded in 2019 by Matt Tindall.
Board
Investors · 5
How we know: the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: WMU Biosciences Research & Commercialization Center's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$9.6M disclosed across 2 rounds · 2020–2023
▶$8.1MraisedOct 2024 · 17 investors · BiotechnologyRule 506(b)
- Curtis ScribnerDirector
- Matthew TindallExecutive Officer, Director
- Cristina LarkinDirector
- Offering amount
- $9M
- Amount sold
- $8.1M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.5MraisedDec 2021 · 1 investors · BiotechnologyRule 506(b)
- Mark P. de SouzaExecutive Officer, Director
- Curtis L. ScribnerExecutive Officer
- Matthew Charles TindallExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.5M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through FlightPath went on to found or lead other companies.
Frequently asked questions
- What does FlightPath do?
- Flightpath Biosciences develops microbiome-sparing, pathogen-specific drug candidates to treat infection-associated diseases by selectively targeting harmful bacteria while preserving healthy microbial communities. The company focuses on small molecule therapeutics for chronic and complex diseases, particularly those linked to pathogenic bacteria such as Crohn's disease.
- Who founded FlightPath?
- FlightPath was founded by Matt Tindall in 2019.
- Who are FlightPath's investors?
- FlightPath's investors include First In Ventures, ID Ventures, Michigan Rise, WMU Biosciences Research & Commercialization Center, Active Capital.
- How much funding has FlightPath raised?
- FlightPath has disclosed $9.6M raised across 2 rounds.
- Where is FlightPath headquartered?
- FlightPath is headquartered in Birmingham, US.